Zura Bio: TibuSHIELD trial in hidradenitis suppurativa didn't meet primary endpoints
Zura Bio announced that the Phase 2 TibuSHIELD study of tibulizumab failed to meet its key efficacy targets in hidradenitis suppurativa, leading the company to discontinue development of the drug in that indication. Concurrently, programs for systemic sclerosis and polymyalgia rheumatica will proceed as planned.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed